Inserm Transfert

Inserm Transfert company information, Employees & Contact Information

Explore related pages

Related company profiles:

Inserm Transfert is the Inserm subsidiary dedicated to value creation and technology transfert in lifescience and human health. Inserm Transfert, the private subsidiary of the French National Institute of the Health and Medical Research (Inserm), is responsible for value creation of Inserm innovations in human health and promotes long-term technology transfers in line with international best practices. Inserm Transfert SA was founded in 2000, and manages, under a Public Service Management Contract (Délégation de Service Public), the entire promotion and transfer of knowledge emerging from the Inserm research laboratories to the industrial world, from invention disclosure to industrial partnerships and startups incorporation. Inserm Transfert also offers services relating to setting up and managing national, European and international projects, as well as supporting the technology transfer of clinical research and health data/databases. In 2009, Inserm Transfert and Inserm established an investment fund to finance proofs of concept. In 2005, Inserm Transfert Initiative, a dedicated seed money fund for life sciences, was created. Since 2017 a pathway for pre-entrepreneurship supports researchers/inventors that aspire to become involved in entrepreneurship.

Company Details

Employees
119
Founded
-
Address
Paris Biopark, 7 Rue Watt,france
Phone
33 1 55 03 01 00
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
PARIS, FRANCE
Looking for a particular Inserm Transfert employee's phone or email?

Inserm Transfert Questions

News

OSE Immunotherapeutics, Inserm Transfert and Nantes - GlobeNewswire

OSE Immunotherapeutics, Inserm Transfert and Nantes GlobeNewswire

Value Creation and Transfer of New Discoveries - Inserm

Value Creation and Transfer of New Discoveries Inserm

MSDAVENIR and Inserm sign a strategic framework agreement - Inserm

MSDAVENIR and Inserm sign a strategic framework agreement Inserm

Inserm and AstraZeneca join forces to test the efficacy of monoclonal antibody combination AZD7442 on Covid-19 in the European DisCoVeRy trial - Inserm

Inserm and AstraZeneca join forces to test the efficacy of monoclonal antibody combination AZD7442 on Covid-19 in the European DisCoVeRy trial Inserm

Sebia Partners with Inserm Transfert - Technology Networks

Sebia Partners with Inserm Transfert Technology Networks

Valérie Crépel, 2022 Innovation Prize - Inserm

Valérie Crépel, 2022 Innovation Prize Inserm

Metastatic Lung Cancer: A Targeted Therapy to Improve Treatment Efficacy - Inserm

Metastatic Lung Cancer: A Targeted Therapy to Improve Treatment Efficacy Inserm

Sophie Balmer - Memorial Sloan Kettering Cancer Center

Sophie Balmer Memorial Sloan Kettering Cancer Center

Inserm Research Director Jérôme Galon Wins European Inventor Award 2019 - Inserm

Inserm Research Director Jérôme Galon Wins European Inventor Award 2019 Inserm

Francine Behar-Cohen, 2021 Innovation Prize - Inserm

Francine Behar-Cohen, 2021 Innovation Prize Inserm

Biomodex plans 3D organ-printing plant for preoperation preparation in Boston - Fierce Biotech

Biomodex plans 3D organ-printing plant for preoperation preparation in Boston Fierce Biotech

Jérôme Galon: A pioneering researcher in cancer immunology - Inserm

Jérôme Galon: A pioneering researcher in cancer immunology Inserm

Huntington’s disease: therapeutic potential of triheptanoin confirmed - Inserm

Huntington’s disease: therapeutic potential of triheptanoin confirmed Inserm

PREVAC-UP: The Partnership for Research on Ebola Vaccination extends follow-up and builds research capacity against deadly disease - Inserm

PREVAC-UP: The Partnership for Research on Ebola Vaccination extends follow-up and builds research capacity against deadly disease Inserm

Boehringer looks into Eyevensys - - Global Corporate Venturing

Boehringer looks into Eyevensys - Global Corporate Venturing

OSE Immunotherapeutics, Inserm Transfert et Nantes - GlobeNewswire

OSE Immunotherapeutics, Inserm Transfert et Nantes GlobeNewswire

Probiotic Bacteria Produces Potent Analgesic - Inserm

Probiotic Bacteria Produces Potent Analgesic Inserm

Inserm in the world Top 10 most innovative public bodies, up one place compared to last year. - Inserm

Inserm in the world Top 10 most innovative public bodies, up one place compared to last year. Inserm

Audrey Ferreira - Sciences Po

Audrey Ferreira Sciences Po

FIBRO-TARGETS – Europe banks on cardiac fibrosis as a therapeutic target in heart failure - Inserm

FIBRO-TARGETS – Europe banks on cardiac fibrosis as a therapeutic target in heart failure Inserm

Trial on safety and immunogenicity of Ebola vaccines yields promising results - Inserm

Trial on safety and immunogenicity of Ebola vaccines yields promising results Inserm

The first French cell therapy trial in a form of retinitis pigmentosa on the horizon - Inserm

The first French cell therapy trial in a form of retinitis pigmentosa on the horizon Inserm

Deciphering the energetic code of cells for better anticancer therapies - Centre national de la recherche scientifique (CNRS)

Deciphering the energetic code of cells for better anticancer therapies Centre national de la recherche scientifique (CNRS)

New cell senescence discoveries open up therapeutic avenues in fighting age-related diseases - Inserm

New cell senescence discoveries open up therapeutic avenues in fighting age-related diseases Inserm

A medical first: CLOVES Syndrome and overgrowth syndromes: remarkable improvement in the health of 19 paediatric and adult patients using a new therapeutic strategy - Inserm

A medical first: CLOVES Syndrome and overgrowth syndromes: remarkable improvement in the health of 19 paediatric and adult patients using a new therapeutic strategy Inserm

Reuters Ranking: CEA, CNRS and Inserm in the Top 10 worldwide research institutions for innovation - Inserm

Reuters Ranking: CEA, CNRS and Inserm in the Top 10 worldwide research institutions for innovation Inserm

Europe is joining forces against neglected parasitic diseases - Inserm

Europe is joining forces against neglected parasitic diseases Inserm

Auto-immune disease: the viral route is confirmed - Inserm

Auto-immune disease: the viral route is confirmed Inserm

Hepcidin, iron hormone in the skin: a new target in the treatment of psoriasis? - Inserm

Hepcidin, iron hormone in the skin: a new target in the treatment of psoriasis? Inserm

Type 2 diabetes: discovery of a new biological cardiovascular risk marker - Inserm

Type 2 diabetes: discovery of a new biological cardiovascular risk marker Inserm

Red blood cell fragments attack blood vessels - Inserm

Red blood cell fragments attack blood vessels Inserm

Improving the treatment of anaemia thanks to a new discovery in iron metabolism - Inserm

Improving the treatment of anaemia thanks to a new discovery in iron metabolism Inserm

Top Inserm Transfert Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant